History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change*

HIV Medicine

Volumn 11, Issue 7, 2010, Pages 469-478

  Reekie, J ^a   Mocroft, A ^a   Ledergerber, B ^b   Beniowski, M ^c   Clotet, B ^d   van Lunzen, J ^e   Chiesi, A ^f   Pradier, C ^g   Machala, L ^h   Lundgren, J D ^i,j  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Specialistic Hospital   (Poland)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j Rigshospitalet   (Denmark)

more..

Author keywords

Antiretroviral therapy; Viral rebound; Virological failure; Virological suppression

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; POISSON DISTRIBUTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 77954349138     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00816.x     Document Type: Article

References (36)

1. Pozniak A, Gazzard B, Anderson J. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003, 4((Suppl. 1)):1-41.
2. http://www.euro.who.int/Document/E90840.pdf, WHO., HIV/AIDS treatment and care: Clinical protocol for the WHO European Region. 2006. Available at, (accessed 1 February 2009).
3. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, Panel on Antiretroviral Guidelines for Adults and Adolescents., Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Departments of Health and Humane Services 2009; 1-161. Available at, (accessed 9 December 2009).
4. Gazzard BG. British HIV association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608.
5. Barreiro PM, Dona MC, Castilla J, Soriano V. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. AIDS 1999, 13:525-526.
6. Phillips AN, Ledergerber B, Horban A. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004, 18:1795-1804.
7. Ledergerber B, Lundgren JD, Walker AS. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004, 364:51-62.
8. Telenti A, Munzo M, Bleiber G, Ledergerber B, Kauffman D. Heterogeneity in the response to antiretroviral therapy. AIDS Rev 1999, 1:147-155.
9. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001, 15:2251-2257.
10. Katlama C, Ghosn J. Clinical trials for heavily pretreated patients: updated in 2006. Curr Opin HIV AIDS 2006, 1:495-501.
11. Bannister WP, Kirk O, Gatell JM. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 2006, 42:229-237.
12. Lampe FC, Gatell JM, Staszewski S. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006, 166:521-528.
13. Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005, 39:195-198.
14. Mocroft A, Ruiz L, Reiss P. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003, 17:1741-1751.
15. Phillips AN, Staszewski S, Lampe F. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002, 186:1086-1091.
16. Benzie AA, Bansi LK, Sabin CA. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007, 21:1423-1430.
17. Bansi LK, Benzie AA, Phillips AN. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008, 22:349-356.
18. Paris D, Ledergerber B, Weber R. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999, 15:1631-1638.
19. Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis 2003, 37:1517-1526.
20. Paredes R, Mocroft A, Kirk O. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000, 160:1123-1132.
21. Paterson DL, Swindells S, Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
22. Oette M, Kroidl A, Gobels K. Predictors of short-term success of antiretroviral therapy in HIV infection. J Antimicrob Chemother 2006, 58:147-153.
23. Bangsberg DR, Perry S, Charlebois ED. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001, 15:1181-1183.
24. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002, 17:812-813.
25. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008, 61:769-773.
26. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, 30((Suppl. 2)):S171-S176.
27. Bangsberg DR, Acosta EP, Gupta R. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006, 20:223-231.
28. Mocroft A, Ledergerber B, Katlama C. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003 5, 362:22-29.
29. Van Laethem K, Deforche K, Geretti AM, Camacho R, Vandamme A. http://www.rega.kuleuven.be/cev/fileadmin/algorithms/Rega_HIV1_Rules_v7.1.1.pdf, Algorithm for the use of genotypic HIV-1 resistance data. Rega v7.1.1, Leuven, 5 July 2007. Available at, (accessed 22 October 2008).
30. Lapadula G, Torti C, Maggiolo F. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+T-cell counts > or =200 cells/mm3. Antivir Ther 2007, 12:941-947.
31. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006, 7:437-441.
32. Easterbrook PJ, Ives N, Waters A. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS 2002, 16:1521-1527.
33. Raffanti SP, Fusco JS, Sherrill BH. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004, 37:1147-1154.
34. Ledergerber B, Egger M, Opravil M. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
35. Kong HH, Myers SA. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. Dermatol Ther 2005, 18:58-66.
36. Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002, 16:1617-1626.